Catalyst
Slingshot members are tracking this event:
Pfizer (PFE) Presents Phase 3b/4 ORAL Strategy Data Evaluating XELJANZ + Methotrexate (MTX) Compared to AbbVie's (ABBV) Humira in Moderate-to-Severe Rheumatoid Arthritis (RA)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3b/4, Oral Strategy, Xeljanz, Methotrexate, Humira, Moderate-to-severe Rheumatoid Arthritis
